Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCTJAM)

• Drug Name: PYRIPYROPENE A Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11828024
  ChEBI ID: CHEBI:64695
  CAS Number: CAS 147444-03-9
  TTD Drug ID: DMCTJAM

Molecule-Related Drug Atlas

Drug(s) Targeting Liver carboxylesterase (CES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[3]
PACTIMIBE	DM0NZDT	Arteriosclerosis	BD40	Phase 2/3	[4]
K-604	DMQVN6P	Arteriosclerosis	BD40	Phase 2	[5]
Eldacimibe	DML7WP0	Hyperlipidaemia	5C80	Phase 2	[6]
GR148672X	DM7W6YN	Acute lymphoblastic leukaemia	2A85	Clinical trial	[7]
Avasimibe	DMFG4OM	Peripheral vascular disease	BD4Z	Discontinued in Phase 3	[8]
E-5324	DM562BM	Hyperlipidaemia	5C80	Discontinued in Phase 2	[9]
RP-64477	DMTQ3BS	Hyperlipidaemia	5C80	Discontinued in Phase 2	[10]
CI-976	DMBO28J	Hyperlipidaemia	5C80	Discontinued in Phase 2	[11]
CL-283796	DM7LIDT	Hyperlipidaemia	5C80	Discontinued in Phase 2	[12]

Drug(s) Targeting SOAT2 messenger RNA (SOAT2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oleic acid anilide	DMXCSVH	Discovery agent	N.A.	Investigative	[13]
ISIS 140158	DMO87PG	Discovery agent	N.A.	Investigative	[14]
ISIS 140153	DMD60BA	Discovery agent	N.A.	Investigative	[14]
ISIS 140157	DMG2P7B	Discovery agent	N.A.	Investigative	[14]
ISIS 140148	DMKYWQ2	Discovery agent	N.A.	Investigative	[14]
ISIS 140161	DMRHSY6	Discovery agent	N.A.	Investigative	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Liver carboxylesterase (CES1)	TTMF541	EST1_HUMAN	Inhibitor	[2]
SOAT2 messenger RNA (SOAT2 mRNA)	TTAK0IN	SOAT2_HUMAN	Inhibitor	[1]

References

• [1] Saucerneol B derivatives as human acyl-CoA: cholesterol acyltransferase inhibitors. Bioorg Med Chem Lett. 2005 Jan 17;15(2):385-8.
• [2] Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4277-80.
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
• [5] A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
• [6] Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
• [8] New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
• [9] Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
• [10] RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
• [11] Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
• [12] ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
• [13] Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5580-3.
• [14] US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.